Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 54: 768-769, 2008; 10.1373/clinchem.2008.103150
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hollensead, S. C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hollensead, S. C.
Related Collections
Right arrow Clinical Case Studies
(Clinical Chemistry. 2008;54:768-769.)
© 2008 American Association for Clinical Chemistry, Inc.

Clinical Case Study

Commentary

Sandra C. Hollensead

Department of Pathology and Laboratory Medicine, University of Louisville Hospital, Louisville, Kentucky.

aAddress correspondence to the author at: Department of Pathology and Laboratory Medicine, University of Louisville Hospital, Louisville, Kentucky, 40292. e-mail scholl01@gwise.louisville.edu.

The first 20% of the full text of this article appears below.

Understanding of thrombin formation in vivo has been greatly enhanced by the development of a cell-based model of coagulation. In this model, all clotting is initiated by the combination of tissue factor and activated coagulation factor VII (FVIIa). The source of the tissue factor may be extravascular or intravascular. Once initial thrombin is formed, . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Association for Clinical Chemistry.